6. Needle-free electronically-controlled jet injector treatment with bleomycin and lidocaine is effective and welltolerated in patients with recalcitrant keloids. 169 6. REFERENCES 1. Uitto J. IL-6 signaling pathway in keloids: a target for pharmacologic intervention? J Invest Dermatol. Jan 2007;127(1):6-8. doi:S0022-202X(15)33097-9 [pii] 10.1038/sj.jid.5700604 2. Ogawa R. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis. Int J Mol Sci. Mar 10 2017;18(3) 3. Ogawa R, Akita S, Akaishi S, et al. Diagnosis and Treatment of Keloids and Hypertrophic Scars-Japan Scar Workshop Consensus Document 2018. Burns Trauma. 2019;7:39. doi:175 [pii]10.1186/s41038-019-0175-y 4. Sitaniya S, Subramani D, Jadhav A, Sharma YK, Deora MS, Gupta A. Quality-of-life of people with keloids and its correlation with clinical severity and demographic profiles. Wound Repair Regen. May 2022;30(3):409-416. doi:10.1111/wrr.13015 5. Halim AS, Emami A, Salahshourifar I, Kannan TP. Keloid scarring: understanding the genetic basis, advances, and prospects. Arch Plast Surg. May 2012;39(3):184-9. doi:10.5999/aps.2012.39.3.184 6. Chike-Obi CJ, Cole PD, Brissett AE. Keloids: pathogenesis, clinical features, and management. Semin Plast Surg. Aug 2009;23(3):178-84. doi:10.1055/s-0029-1224797 7. Nakashima M, Chung S, Takahashi A, et al. A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population. Nat Genet. Sep 2010;42(9):768-71. doi:ng.645 [pii]10.1038/ng.645 8. Kiprono SK, Chaula BM, Masenga JE, Muchunu JW, Mavura DR, Moehrle M. Epidemiology of keloids in normally pigmented Africans and African people with albinism: population-based cross-sectional survey. Br J Dermatol. Sep 2015;173(3):852-4. doi:10.1111/bjd.13826 9. Amadeu T, Braune A, Mandarim-de-Lacerda C, Porto LC, Desmouliere A, Costa A. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis. Pathol Res Pract. 2003;199(7):469-73. doi:S0344-0338(04)70445-8 [pii]10.1078/03440338-00447
RkJQdWJsaXNoZXIy MTk4NDMw